Cart
sales@molnova.com
Doramapimod
CAS No. 285983-48-4
Doramapimod( BIRB 796 | BIRB-796 | BIRB796 )
Catalog No. M13869 CAS No. 285983-48-4
A highly potent p38 MAPK inhibitor with Kd of 0.1 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 35 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 48 | In Stock |
|
| 25MG | 68 | In Stock |
|
| 50MG | 86 | In Stock |
|
| 100MG | 120 | In Stock |
|
| 200MG | 220 | In Stock |
|
| 500MG | 370 | In Stock |
|
| 1G | 551 | In Stock |
|
Biological Information
-
Product NameDoramapimod
-
NoteResearch use only, not for human use.
-
Brief DescriptionA highly potent p38 MAPK inhibitor with Kd of 0.1 nM.
-
DescriptionA highly potent p38 MAPK inhibitor with Kd of 0.1 nM; displays no activity on ERK1, IKK2b, ZAP-70, EGFR, PKA, PKC, etc.; shows inhibition of TNFα inTHP.1 with IC50 of 18 nM; orally active.
-
In Vitro——
-
In Vivo——
-
SynonymsBIRB 796 | BIRB-796 | BIRB796
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38α
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number285983-48-4
-
Formula Weight527.6572
-
Molecular FormulaC31H37N5O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(NC1=C2C=CC=CC2=C(OCCN3CCOCC3)C=C1)NC4=CC(C(C)(C)C)=NN4C5=CC=C(C)C=C5
-
Chemical NameUrea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pargellis C, et al. Nat Struct Biol. 2002 Apr;9(4):268-72.
2. Regan J, et al. J Med Chem. 2002 Jul 4;45(14):2994-3008.
3. Gruenbaum LM, et al. Biochem Pharmacol. 2009 Feb 1;77(3):422-32.
molnova catalog
related products
-
mulberroside B
Antitussive, antiasthmatic, hypoglycemic, anti - tumor, treatment of gout.
-
SR-318
SR-318 potently inhibits the TNF-α release in whole blood (IC50 = 283 nM). SR-318 is a potent and highly selective inhibitor of p38 MAPK. The IC50 values are 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively.
-
Darizmetinib
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
